Wave Life Sciences WVE Stock
Wave Life Sciences Price Chart
Wave Life Sciences WVE Financial and Trading Overview
Wave Life Sciences stock price | 5.8 USD |
Previous Close | 4.06 USD |
Open | 4.03 USD |
Bid | 0 USD x 800 |
Ask | 0 USD x 900 |
Day's Range | 3.87 - 4.1 USD |
52 Week Range | 1.87 - 7.12 USD |
Volume | 200.4K USD |
Avg. Volume | 332.8K USD |
Market Cap | 384.63M USD |
Beta (5Y Monthly) | -0.912323 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.7 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.71 USD |
WVE Valuation Measures
Enterprise Value | 221.56M USD |
Trailing P/E | N/A |
Forward P/E | -2.9621212 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 25.939718 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 14.942 |
Enterprise Value/EBITDA | -1.491 |
Trading Information
Wave Life Sciences Stock Price History
Beta (5Y Monthly) | -0.912323 |
52-Week Change | 98.47% |
S&P500 52-Week Change | 20.43% |
52 Week High | 7.12 USD |
52 Week Low | 1.87 USD |
50-Day Moving Average | 4.06 USD |
200-Day Moving Average | 4.32 USD |
WVE Share Statistics
Avg. Volume (3 month) | 332.8K USD |
Avg. Daily Volume (10-Days) | 243.68K USD |
Shares Outstanding | 98.37M |
Float | 42.16M |
Short Ratio | 4.76 |
% Held by Insiders | 25.15% |
% Held by Institutions | 70.21% |
Shares Short | 1.78M |
Short % of Float | 2.77% |
Short % of Shares Outstanding | 1.80% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -1044.71% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -44.55% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 14.83M USD |
Revenue Per Share (ttm) | 0.17 USD |
Quarterly Revenue Growth (yoy) | 638.79% |
Gross Profit (ttm) | N/A |
EBITDA | -148634000 USD |
Net Income Avi to Common (ttm) | -151414000 USD |
Diluted EPS (ttm) | -1.57 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 207.56M USD |
Total Cash Per Share (mrq) | 2.11 USD |
Total Debt (mrq) | 36.61M USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 1.656 |
Book Value Per Share (mrq) | -0.354 |
Cash Flow Statement
Operating Cash Flow (ttm) | -2386000 USD |
Levered Free Cash Flow (ttm) | 1.31M USD |
Profile of Wave Life Sciences
Country | United States |
State | N/A |
City | Singapore |
Address | Marina One East Tower |
ZIP | 018936 |
Phone | 65 6236 3388 |
Website | https://www.wavelifesciences.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 250 |
Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.
Q&A For Wave Life Sciences Stock
What is a current WVE stock price?
Wave Life Sciences WVE stock price today per share is 5.8 USD.
How to purchase Wave Life Sciences stock?
You can buy WVE shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Wave Life Sciences?
The stock symbol or ticker of Wave Life Sciences is WVE.
Which industry does the Wave Life Sciences company belong to?
The Wave Life Sciences industry is Biotechnology.
How many shares does Wave Life Sciences have in circulation?
The max supply of Wave Life Sciences shares is 153.49M.
What is Wave Life Sciences Price to Earnings Ratio (PE Ratio)?
Wave Life Sciences PE Ratio is now.
What was Wave Life Sciences earnings per share over the trailing 12 months (TTM)?
Wave Life Sciences EPS is -0.7 USD over the trailing 12 months.
Which sector does the Wave Life Sciences company belong to?
The Wave Life Sciences sector is Healthcare.
Wave Life Sciences WVE included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
9.99B USD — | 14784.03 USD — | 16292.28 USD — | — - | 9.99B USD — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
NASDAQ Global Market Composite NQGM | 1638.71 USD — |
-0.55
|
— — | 1547.55 USD — | 1705.12 USD — | — - | — — |
NASDAQ Biotechnology NBI | 3856.67 USD — |
-1.22
|
— — | 3700.88 USD — | 3966.57 USD — | — - | — — |
NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
- {{ link.label }} {{link}}